相似文献
1
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
Antimicrob Agents Chemother. 2010 Apr;54(4):1627-32. doi: 10.1128/AAC.01788-09. Epub 2010 Jan 25.
2
Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds.
Diagn Microbiol Infect Dis. 2013 Jul;76(3):347-51. doi: 10.1016/j.diagmicrobio.2013.03.019. Epub 2013 Apr 24.
3
Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2014;58(1):559-62. doi: 10.1128/AAC.01358-13. Epub 2013 Nov 11.
4
In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
Antimicrob Agents Chemother. 2011 Jan;55(1):421-5. doi: 10.1128/AAC.00868-10. Epub 2010 Nov 1.
5
Comparative anti-anaerobic activity of Men 10700, a penem antibiotic.
Int J Antimicrob Agents. 1998 Nov;10(4):321-4. doi: 10.1016/s0924-8579(98)00052-1.
6
Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Int J Antimicrob Agents. 2014 Dec;44(6):514-9. doi: 10.1016/j.ijantimicag.2014.07.027. Epub 2014 Sep 24.
7
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Diagn Microbiol Infect Dis. 2007 May;58(1):133-6. doi: 10.1016/j.diagmicrobio.2006.10.015. Epub 2007 Jan 19.
8
Activity of linezolid against anaerobic bacteria.
Int J Antimicrob Agents. 2003 Jul;22(1):28-34. doi: 10.1016/s0924-8579(03)00087-6.
9
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Diagn Microbiol Infect Dis. 2014 Apr;78(4):422-8. doi: 10.1016/j.diagmicrobio.2013.08.027. Epub 2014 Jan 18.
10
Ceftaroline: a new broad-spectrum cephalosporin.
Am J Health Syst Pharm. 2011 Mar 15;68(6):491-8. doi: 10.2146/ajhp100181.
引用本文的文献
1
Antibiotic therapy for bacterial pneumonia.
J Pharm Health Care Sci. 2024 Jul 30;10(1):45. doi: 10.1186/s40780-024-00367-5.
2
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1304. doi: 10.3390/ph16091304.
3
Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis.
Antibiotics (Basel). 2022 Sep 22;11(10):1291. doi: 10.3390/antibiotics11101291.
4
Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
BMC Pulm Med. 2020 Jun 5;20(1):160. doi: 10.1186/s12890-020-01198-4.
5
Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Drugs. 2016 Nov;76(17):1659-1674. doi: 10.1007/s40265-016-0654-4.
6
Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3178-82. doi: 10.1128/AAC.03126-15. Print 2016 May.
7
Ceftaroline fosamil: a brief clinical review.
Infect Dis Ther. 2013 Dec;2(2):95-110. doi: 10.1007/s40121-013-0010-x. Epub 2013 Aug 8.
8
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
Antimicrob Agents Chemother. 2014 May;58(5):2541-6. doi: 10.1128/AAC.02371-13. Epub 2014 Feb 18.
9
In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.
10
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
本文引用的文献
1
Ceftaroline: a cephalosporin with expanded Gram-positive activity.
Future Microbiol. 2009 Feb;4(1):25-33. doi: 10.2217/17460913.4.1.25.
2
Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Int J Antimicrob Agents. 2009 Jun;33(6):515-9. doi: 10.1016/j.ijantimicag.2008.12.005. Epub 2009 Feb 8.
3
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Antimicrob Agents Chemother. 2008 Sep;52(9):3398-407. doi: 10.1128/AAC.00149-08. Epub 2008 Jul 14.
4
National hospital survey of anaerobic culture and susceptibility methods: III.
Anaerobe. 2008 Apr;14(2):68-72. doi: 10.1016/j.anaerobe.2008.01.001. Epub 2008 Jan 11.
5
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Curr Opin Investig Drugs. 2008 Feb;9(2):201-9.
6
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Mar;52(3):1153-5. doi: 10.1128/AAC.01351-07. Epub 2008 Jan 7.
7
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Antimicrob Agents Chemother. 2007 Oct;51(10):3612-6. doi: 10.1128/AAC.00590-07. Epub 2007 Aug 6.
8
Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
J Clin Microbiol. 2007 Sep;45(9):2819-28. doi: 10.1128/JCM.00551-07. Epub 2007 Jul 3.
9
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
10
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
J Antimicrob Chemother. 2007 Aug;60(2):300-11. doi: 10.1093/jac/dkm150. Epub 2007 Jun 4.
Zotero 插件